ICER Policy Proposals for Orphan Drug Pricing
The Institute for Clinical and Economic Review (ICER) recently published the white paper “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.” Read on to learn what it means for science manufacturers.